In this episode of our hematology podcast, we delved into the realm of relapsed and refractory multiple myeloma with Dr. Samir Al-Hadidi from the University of Arkansas. The discussion highlighted the evolving treatment landscape for patients who experience relapse or disease progression after initial therapies.
Dr. Al-Hadidi emphasized the importance of monitoring patients on maintenance therapy for relapse. When it comes to escalating treatments for relapsed patients, the introduction of anti-CD38-based regimens with companion drugs like proteasome inhibitors or immunomodulators was discussed as a common approach.
The conversation also touched upon the role of CAR-T cell therapy and bispecific antibodies in the treatment of multiple myeloma, with Dr. Al-Hadidi stressing the need for collaboration between community oncologists and specialized centers to ensure access to these advanced therapies. The discussion further explored the side effects and supportive care required for patients undergoing CAR-T or bispecific treatments.
Dr. Al-Hadidi provided insights into the use of Selenexor and bispecific antibodies, highlighting the efficacy and considerations for choosing between BCMA-based and GPRC5D-based therapies. The importance of considering older drugs like alkylators and personalized treatments like venetoclax for specific patient subsets was also emphasized.
Overall, the episode underscored the dynamic nature of multiple myeloma treatment options and the crucial role of community oncologists in managing relapsed and refractory cases effectively. Collaboration, monitoring for side effects, and staying informed about emerging therapies were key takeaways for listeners navigating the complex landscape of multiple myeloma treatment.
